Previous 10 | Next 10 |
ABC, ABUS, ACIW, ADAP, AES, AHCO, AKBA, ALBO, ALE, APD, APTV, ARW, ASPS, ATNX, ATRA, ATRS, BCE, BDX, BLDR, BLI, BLL, BRG, BXRX, CARS, CCOI, CFX, CHH, CI, CLDT, CMRX, CNHI, CNP, CNQ, COMM, CPE, CS, CTXS, CWEN, CYBR, DBRG, DEN, DIN, DISH, DLX, DNB, DOCN, DUK, EPAM, ERJ, ESTE, EURN, EVA, FIS, FW...
Albireo Pharma (NASDAQ:ALBO) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is $0.49 and the consensus Revenue Estimate is $17.05M (+700.5% Y/Y). Over the last 3 months, EPS estimates have seen 4 upward revisions and 3 do...
BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on November 4, 2021, to provide a ...
– Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases – – Phase 3 Bylvay™ (odevixibat) data presentations on long-term treatment benefits show evidence of improved liver health and function across PFIC type...
– Agreement to accelerate commercialization of Bylvay ™ (odevixibat) in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia – – Albireo to receive upfront payment of $15M and up to $120M in milestones and doub...
BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2021, a global effort to support pati...
– Listed on the German national price list and all pharmacy software programs – – Bylvay is approved in U.S., EU and UK as first drug treatment for patients with PFIC – – Only once-daily drug indicated to treat all forms of ...
– Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC – – Only once-daily drug indicated to treat all forms of PFIC – – MHRA decision based on data from the largest Phase 3 PFIC trial to dat...
– PRV was granted to Albireo with the FDA approval of Bylvay TM (odevixibat) in July – – Non-dilutive capital further strengthens the Company’s financial position – BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc....
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of t...
News, Short Squeeze, Breakout and More Instantly...
Albireo Pharma Inc. Company Name:
ALBO Stock Symbol:
NASDAQ Market:
Bylvay (odevixibat) granted Priority Review by U.S. FDA ASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patients Approval in second indication would more than double Bylvay market oppo...
Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca , while Albireo Pharma (NASDAQ: ALBO) is set to be owned by ...
The Nasdaq Composite (NASDAQINDEX: ^IXIC) might finally be looking to gain some momentum in 2023, with investors desperately wanting a reversal from 2022's horrible performance. Sizable gains on Friday helped to build more positive sentiment, and the bullish move continued on Monday morni...